Molecular structure of P2Y receptors: Mutagenesis, modeling, and chemical probes

Wiley Interdisciplinary Reviews: Membrane Transport and Signaling

Volumn 1, Issue 6, 2012, Pages 815-827

  Jacobson, Kenneth A ^a   Jayasekara, M P Suresh ^a   Costanzi, Stefano ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b AMERICAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PURINERGIC P2 RECEPTOR; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y13 RECEPTOR; PURINERGIC P2Y14 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; UNCLASSIFIED DRUG;

MOLECULAR MODEL; MOLECULAR PROBE; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS;

EID: 84874616139     PISSN: 2190460X     EISSN: 21904618     Source Type: Journal    
DOI: 10.1002/wmts.68     Document Type: Review

References (70)

1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Fumagalli M, King BF, Gachet C, Jacobson KA, et al. International Union of Pharmacology LVIII. Update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006, 58:281-341.
2. Bjarnadottir TK, Gloriam DE, Hellstrand SH, Kristiansson H, Fredriksson R, Schiöth HB. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 2006, 88:263-273.
3. Costanzi S, Mamedova L, Gao ZG, Jacobson KA. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem 2004, 47:5393-5404.
4. 11 receptor to phospholipase C and adenylyl cyclase. Br J Pharmacol 2001, 132:318-326.
5. Jacobson KA, Boeynaems J-M. P2Y nucleotide receptors: promise of therapeutic applications. Drug Disc Today 2010, 15:570-578.
6. 12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007, 17:6013-6018.
7. Erb L, Garrad R, Wang Y, Quinn T, Turner JT, Weisman GA. Site-directed mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J Biol Chem 1995, 270:4185-4188.
8. 1 receptor. Mol Pharmacol 1997, 52:499-507.
9. 1receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 1998, 41:1456-1466.
10. 11 nucleotide receptor: mutational analysis. Br J Pharmacol 2008, 155:1250-1255.
11. 1 receptor. Drug Dev Res 2002, 57:173-181.
12. 2 receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J Med Chem 2009, 52:2762-2775.
13. 1 receptor in surface expression and activation processes. J Biol Chem 1999, 274:14639-14647.
14. 12-receptor. Biochem Pharmacol 2008, 76:1201-1213.
15. 12 receptor. J Pharm Exp Ther 2009, 331:648-655.
16. 11 receptors. Mol Pharmacol 2001, 60:1375-1382.
17. 11 nucleotide receptor deduced from computational modelling and mutational analysis. Biochem J 2007, 405:277-286.
18. 12 receptor. Eur J Pharmacol 2010, 644:10-16.
19. 2 receptor and design of a selective agonist, 2′-amino-2′-deoxy-2-thiouridine 5′-triphosphate. J Med Chem 2007, 50:1166-1176.
20. 1 receptor ligands. J Med Chem 2000, 43:829-842.
21. 1-receptor. J Med Chem 2004, 47:4405-4416.
22. 4 receptors. Biochem Pharmacol 2006, 71:540-549.
23. 6 receptor. J Med Chem 2006, 49:5532-5543.
24. 4 receptor. J Med Chem 2011, 54:4018-4033.
25. Yelovitch S, Barr HM, Camden J, Weisman GA, Shai E, Varon D, Fischer B. Identification of a Promising Drug Candidate for the Treatment of Type 2 Diabetes Based on a P2Y1 Receptor Agonist. J Med Chem 2012. DOI: 10.1021/jm 3006355.
26. Brunschweiger A, Müller CE. P2 receptors activated by uracil nucleotides-an update. Curr Med Chem 2006, 13:289-312.
27. 1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett 2008, 18:3338-3343.
28. Eliahu S, Barr HM, Camden J, Weisman GA, Fischer B. A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold. J Med Chem 2010, 53:2472-2481.
29. 6 receptors. J Med Chem 2006, 49:7076- 7087.
30. 6 receptors. J Med Chem 2011, 54:2878-2890.
31. van Rhee AM, Fischer B, van Galen PJ, Jacobson KA. Modelling the P2Y purinoceptor using rhodopsin as template.. Drug Des Discov 1995, 13:133-154.
32. Moro S, Jacobson KA. Molecular modeling as a tool to investigate molecular recognition in P2Y receptors. Curr Pharm Des 2002, 8:99-110.
33. 1-receptor. J Med Chem 2004, 47:4391-4404.
34. 12 nucleotide receptor. J Comput Aided Mol Des 2011, 25:329-338.
35. Ballesteros JA, Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In: Conn PM, Sealfon SC, eds. Methods in Neurosciences. Vol. 25. San Diego, CA: Academic Press; 1995, 366-428.
36. Ivanov AA, Costanzi S, Jacobson KA. Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling. J Comput Aided Mol Des 2006, 20:417-426.
37. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289:739-745.
38. Cherezov V, Rosenbaum D, Hanson M, Rasmussen S, Thian F, Kobilka T, Choi H, Kuhn P, Weis W, Kobilka B, et al. High-resolution crystal structure of an engineered human β2 adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
39. Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
40. Baqi Y, Weyler S, Iqbal J, Zimmermann H, Müller CE. Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). Purinergic Signal 2009, 5:91-106.
41. Hechler B, Gachet C. P2 receptors and platelet function. Purinergic Signal 2011, 4:293-303.
42. 13 receptors by conformational constraint of an ADP analogue. J Pharm Exp Ther 2004, 311:1038-1043.
43. 1 receptor. Mol Pharmacol 1996, 50:1323-1329.
44. 6 receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J Med Chem 2005, 48:8108-8111.
45. 1 receptor. Biochem Pharmacol 2004, 68:1995-2002.
46. 1 receptors inhibitors. WO2005070920, August 4, 2005.
47. 1 receptor antagonists. Bioorg Med Chem Lett 2008, 18:6222-6226.
48. 1 receptor antagonists. Bioorg Med Chem Lett 2010, 20:4104-4107.
49. Shaver SR, Rideout JL, Pendergast W, Douglass JG, Brown EG, Boyer JL, Patel RI, Redick CC, Jones AC, Picher M, et al. Structure-activity relationships of dinucleotides: potent and selective agonists of P2Y receptors. Purinergic Signal 2005, 1:183-191.
50. Yerxa BR, Sabater JR, Davis CW, Stutts MJ, Lang-Furr M, Picher M, Jones AC, Cowlen M, Dougherty R, Boyer J, et al. Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)-(2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y2 receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 2002, 302:871-880.
51. 6 receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5′-triphosphate γ-ester modifications. J Med Chem 2010, 53:4488-4501.
52. 2 receptor agonist activity of nucleotide 5′-phosphonate analogues. Bioorg Med Chem 2012, 20:2304-2315.
53. Weyler S, Baqi Y, Hillmann P, Kaulich M, Hunder AM, Müller IA, Müller CE. Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett 2008, 18:223-227.
54. 14. Bioorg Med Chem Lett 2011, 21:2836-2839.
55. 14 receptor. Acta Physiol 2010, 199:149-160.
56. 6-receptor agonist. J Med Chem 2010, 53:1673- 1685.
57. Ginsburg-Shmuel T, Haas M, Grbic D, Arguin G, Nadel Y, Gendron FP, Reiser G, Fischer B. UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety. Bioorg Med Chem 2012. doi:10.1016/j.bmc.2012.07.042. In press.
58. Balasubramanian R, Ruiz de Azua I, Wess J, Jacobson KA. Activation of distinct P2Y receptor subtypes stimulates insulin secretion and cytoprotection in MIN6 mouse pancreatic β cells. Biochem Pharmacol 2010, 79:1317-1326.
59. von Kügelgen I, Harden TK. Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv Pharmacol 2011, 61:373-415.
60. 11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharm Exp Ther 2010, 332:238-247.
61. Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally IJ, Hunt SF, Kindon ND, Teobald BJ, Willis PA, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999, 42:213- 220.
62. 12 receptors. Bioorg Med Chem Lett 2005, 15:5450- 5452.
63. Zhang H, Liu J, Zhang L, Kong L, Yao H, Sun H. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents. Bioorg Med Chem Lett 2012, 22:3598-3602.
64. 12 ADP-receptor antagonist, INS50589. Platelets 2007, 18:346-356.
65. 12 receptors. J Med Chem 2009, 52:3784-3793.
66. 12 antagonists for inhibition of platelet aggregation. J Med Chem 2010, 53:2010-2037.
67. 13 receptor is critical for reverse cholesterol transport. Hepatology 2010, 52:1477-1483.
68. 14 receptors is a mediator of mast cell degranulation. Biochem Pharmacol 2010, 79:873-879.
69. 14 and other P2Y receptors in degranulation of human LAD2 mast cells. Purinergic Signal 2012. In press. DOI: 10.1007/s11302-012-9325-4.
70. 1 receptor antagonists. Bioorg Med Chem 2012, 20:5254-5261.